News & Analysis on Clinical Trial Services & Contract Research And Development
Using a modified version of nuclear magnetic resonance technology, (NMR) scientists have revealed the therapeutic potential of an insect's venom, which could be utilised to provide a better understanding of Alzheimer's disease and other disorders.
Researchers have developed a biochip that could prove crucial in future drug development. The technology measures electrical activities of cells and can obtain 60 times more data in one reading than is possible with current technology.
Developing new drugs represents an enormous expense for pharma companies with top firms spending up to £4bn (€6bn) a year on R&D, according to new industry report.
A new dry powder inhaler that may cost less than a syringe and deliver 40 per cent more active drug than current inhalers has been unveiled by its maker, Cambridge Consultants.
PPD managed a net revenue of $313.1m (€250m) for the third quarter of 2006, an increase of 14.6 per cent over net revenue of $273.3m for the third quarter of 2005. This has been buoyed on by the strong performance by the company's developmental segment.
Findings from new study have offered an innovative profile of an enzyme that aids tumour growth, which points towards a potential new target for treatments for ovarian and breast cancers.
For pharma companies that are hesitant about outsourcing during the drug discovery stage, a world of opportunity awaits. OutsourcingPharma.com gives a brief run down of what kinds of services are on offer, as well as a few potential risks to look out...
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the drug giant has been involved in a joint venture with to manufacture and sell Cialis (tadalafil) - the number two erectile dysfunction drug behind Viagra (sildenafil).
The Food and Drug Administration (FDA) is expected to issue a revised version of its regulation on electronic signatures and records by the end of the year, which will force drug and device companies to reconsider their current information management...
MDS Pharma Services has opened its first central lab in the US, expanding its capabilities in late-stage clinical trial testing.